Physician profile

Maria Lee

Anatomic Pathology & Clinical Pathology · Baltimore, MD

NPI 1477580223

$854.63

in general payments reported to CMS, 2019-2025

6 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$404.66

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Bayer Healthcare Pharmaceuticals INC. $422.79 2021-2023
Werfen USA LLC $255.13 2023
Boehringer Ingelheim Pharmaceuticals, INC. $123.67 2019
Grifols Diagnostic Solutions, INC. $20.46 2019
Tandem Diabetes Care, INC. $16.60 2023 T:Slim X2 Insulin Pump With Control-Iq
Novo Nordisk INC $15.98 2024 Ozempic

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Maria Lee

$854.63

in general payments reported 2019-2025

Years
2019-2024
Top company
Bayer Healthcare Pharmaceuticals INC.

https://glasscript.com/doctor/661576/maria-lee

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.